Anti-KIR3DL2 mAb in refractory Sézary syndrome: IPH4102
Sézary syndrome (SS), the most aggressive form of cutaneous T-cell lymphoma (CTCL), is characterized by a high expression of the KIR3DL2 receptor.
VJHemOnc – Video Journal of Hematological Oncology
How to manage relapsed/refractory MCL - new agents and unmet needs
Tadeusz Robak, MD, PhD from the Medical University of Lodz, Lodz, Poland, discusses the management of relapsed/refractory mantle cell lymphoma (MCL).
VJHemOnc – Video Journal of Hematological Oncology
Phase 1b trial of idelalisib plus chemoimmunotherapy for relapsed/refractory CLL
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, ...
VJHemOnc – Video Journal of Hematological Oncology
Phase 2 study of daratumumab monotherapy for heavily pretreated and refractory multiple myeloma
At the 20th Congress of the European Hematology Association (EHA), Jesús F. San Miguel, MD, of the Clínica Universidad de Navarra, Navarra, Spain, ...
VJHemOnc – Video Journal of Hematological Oncology
What does a physician need to consider when treating relapsed or refractory myeloma?
Mohamad Mohty, MD, PhD from Saint-Antoine Hospital, Paris, France discusses treatment options for relapsed and refractory multiple myeloma (MM) at the ...
VJHemOnc – Video Journal of Hematological Oncology
Efficacy and safety of CD19-targeted CAR T-cells for relapsed/refractory ALL
At the 20th Congress of the European Hematology Association (EHA), Dieter Hoelzer, MD, PhD, of Goethe University Hospital, Frankfurt, Germany, discusses ...
VJHemOnc – Video Journal of Hematological Oncology
Recent investigational advances in the management of relapsed/refractory myeloma
Prof Paul Richardson (Dana-Farber Cancer Institute, Boston, MA) summarises of results of clinical trials in the management of relapsed or refractory multiple ...
VJHemOnc – Video Journal of Hematological Oncology
HELIOS trial: Ibrutinib for relapsed/refractory chronic lymphocytic leukemia
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Jacqueline Barrientos, MD, of the North Shore-LIJ Cancer Institute, Lake Success, ...
VJHemOnc – Video Journal of Hematological Oncology
Ibrutinib vs temsirolimus in relapsed/refractory mantle cell lymphoma
Simon Rule, MD from Derriford Hospital, Plymouth, UK provides an overview of the RAY (MCL3001) study of ibrutinib vs temsirolimus in relapsed/refractory ...
VJHemOnc – Video Journal of Hematological Oncology
Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Sagar Lonial, MD from Emory University Winship Cancer Institute, Atlanta, GA gives an overview of the ELOQUENT-2 clinical trial of ...
VJHemOnc – Video Journal of Hematological Oncology
Single-agent daratumumab activity in refractory multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Maria-Victoria Mateos, MD, PhD, of the University Hospital of Salamanca, ...
VJHemOnc – Video Journal of Hematological Oncology
ASH 2014: Phase II SPRINT study of lenalidomide in relapsed/refractory mantle cell lymphoma
Prof Marek Trněný (Charles University Hospital, Prague, Czech Republic) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses the ...
VJHemOnc – Video Journal of Hematological Oncology
SPRINT trial: Lenalidomide for relapsed/refractory mantle cell lymphoma
Marek Trněný, MD, PhD, of Charles University, Prague, Czech Republic, presents the subgroup analysis of the phase 2 SPRINT trial at the 20th Congress of the ...
VJHemOnc – Video Journal of Hematological Oncology
MMY1001 subgroup: daratumumab-Kd in lenalidomide refractory MM
While there are many clinical trials exploring the effect of various novel agents in combination with lenalidomide-dexamethasone therapy in multiple myeloma ...
VJHemOnc – Video Journal of Hematological Oncology
ASH 2014: Phase II/III study of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
Dr Andrew Davies (University of Southampton, Southampton, UK) at the 2014 American Society of Hematology (ASH) Annual Meeting discusses a phase II/III ...
VJHemOnc – Video Journal of Hematological Oncology
Allo-HSCT and novel drugs for refractory AML
Mohamad Mohty, MD, PhD, Saint-Antoine Hospital, Paris, France, discusses allogeneic hematopoietic cell transplantation (allo-HSCT). In allogeneic HSCT, the ...
VJHemOnc – Video Journal of Hematological Oncology
Refractory multiple myeloma: analyzing MAMMOTH and STORM
Luciano Costa, MD, PhD, UAB School of Medicine, Birmingham, AL, discusses the MAMMOTH and STORM (NCT02336815) studies evaluating selinexor in ...
VJHemOnc – Video Journal of Hematological Oncology
Management of refractory cirrhotic ascites - Video Abstract ID 136578
Video abstract of review paper “Management of refractory cirrhotic ascites: challenges and solutions” published in the open access journal Hepatic Medicine: ...
Dove Medical Press
Advances in therapeutic strategies for patients with relapsed/refractory myeloma
Dr. Jesus F. San-Miguel discusses the advances in the optimal choice of therapeutic strategies for patients with relapsed/refractory disease during the Friday ...
International Myeloma Foundation
Ictal heart rate and effects of vagus stimulation in refractory epilepsy - Video Abstract ID 142714
Video abstract of hypothesis paper “Ictal heart rate changes and the effects of vagus nerve stimulation for patients with refractory epilepsy” published in the open ...
Dove Medical Press
New York Moscow IBD Journal Club - Dr. Ellen J. Scherl
Ellen J. Scherl, M.D., the Director of The Jill Roberts Center for Inflammatory Bowel Disease at NewYork-Presbyterian Hospital in New York City, discusses a ...
NewYork-Presbyterian Hospital
Sacituzumab govitecan for treatment-refractory metastatic breast cancer
Aditya Bardia, MD, MPH, of Massachusetts General Hospital, Boston, MA, discusses the promising efficacy data of sacituzumab govitecan, an anti-Trop-2/SN-38 ...
VJOncology
IV Vitamin C/Ascorbic Acid in the ICU (Journal Club-ish)
Paul Marik may be onto something.... J. Teng, A. Pourmand, M. Mazer-Amirshahi, Vitamin C: The next step in sepsis management?, In Journal of Critical Care, ...
eddyjoemd
Copanlisib for relapsed/refractory NHL: results of the CHRONOS-1 study
Copanlisib is a novel PI3K inhibitor, targeting both PI3K-α and PI3K-δ isoforms in malignant B-cells. It was granted FDA approval based on data from the Phase ...
VJHemOnc – Video Journal of Hematological Oncology
Endoscopic Therapy of Refractory Post-Papillotomy Bleeding - Electrocautery Forceps Coagulation
Abstract: The overall risk of clinically significant post-papillotomy bleeding is 1--4%, most of them manifest as a delayed hemorrhage 2--5 days after ERCP.
Video Journal and Encyclopedia of GI Endoscopy
Refractory Edema with CHF Dr mohamed Abdel Gawad MNDU 2016
Refractory Edema with CHF Dr mohamed Abdel Gawad MNDU 2016.
Academy of Kidney Diseases and Transplantation
TAP funded Tier study for relapsed and refractory CNS lymphoma patients
Christopher Fox, MBChB, MRCP, FRCPath, from Nottingham University Hospital, Nottingham, UK discusses the Tier study at the 2017 British Society for ...
VJHemOnc – Video Journal of Hematological Oncology
Treating highly relapsed/refractory CLL
Michael Hallek, MD, of the University Hospital of Cologne, Cologne, Germany, outlines treatment options for relapsed/refractory patients with chronic lymphocytic ...
VJHemOnc – Video Journal of Hematological Oncology
Regorafenib in refractory biliary tract cancer
Richard Kim, MD, Moffitt Cancer Center, Tampa, FL, explores results from a Phase II study evaluating the use of regorafenib, a tyrosine kinase inhibitor, ...
VJOncology
Surgical Management of Refractory Bladder Neck Contracture after BPH Surgery
Brian J. Flynn, MD, identifies the frequency of bladder neck contracture (BNC) following benign prostatic hyperplasia (BPH) surgery, prevention strategies, and ...
Grand Rounds in Urology
The devastating effects of relapsed or refractory AML
Dealing with patients with refractory acute myeloid leukemia (AML) or with those who have relapsed, is challenging, and stem cell transplantation is one of the ...
VJHemOnc – Video Journal of Hematological Oncology
Heterogeneity in refractory AML
Refractory acute myeloid leukemia (AML) has a poorly understood biology and prognosis. Here Christopher Hourigan, DM, DPhil, FACP, FRCP, of the National ...
VJHemOnc – Video Journal of Hematological Oncology
Flotetuzumab for primary refractory and early relapsed AML
John DiPersio, MD, PhD, Washington University School of Medicine, Saint Louis, MO, presents additional scientific data supporting the investigation of ...
VJHemOnc – Video Journal of Hematological Oncology
Therapeutic Options in Patients with Refractory Angina | Shmuel Banai
Therapeutic Options in Patients with Refractory Angina Shmuel Banai Tel-Aviv Sourasky Medical Center, Cardiology, Tel-Aviv, Israel.
האיגוד הקרדיולוגי בישראל
Online Urology Journal Club: Metastatic Hormone Refractory Prostate Cancer at SIUT on 7th July 2020.
Online Urology Journal Club: Metastatic Hormone Refractory Prostate Cancer at SIUT on 7th July 2020.
SIUT
Phase III Data for Relapsed/Refractory Myeloma
OncLiveTV
CAR T-cells for B-ALL- Video Abstract ID 146309
Video abstract of review paper “The potential of CAR T therapy for relapsed or refractory pediatric and young adult B-cell ALL” published in the open access ...
Dove Medical Press
Approaching Therapy for Relapsed/Refractory CLL
Matthew S. Davids, MD, and Michael Choi, MD, give their considerations for risk stratification and therapy selection in the relapsed/refractory setting of chronic ...
OncLiveTV
Immunotherapy for reducing the rate of relapsed/refractory ALL
In this video, Daniel DeAngelo, MD, PhD, of the Dana-Farber Cancer Institute, Boston, MA, talks about how novel immunotherapeutic options could reduce the ...
VJHemOnc – Video Journal of Hematological Oncology
ELOQUENT-2: Elotuzumab for relapsed/refractory multiple myeloma
At the 2015 American Society of Clinical Oncology (ASCO) Annual Meeting, Joseph R. Mikhael, MD, of Mayo Clinic, Scottsdale, AZ, discusses the results of the ...
EMG-Health
Dr. Mailankody on BCMA CAR T-Cell Therapy in Relapsed/Refractory Multiple Myeloma
Sham Mailankody, MBBS, assistant attending physician, Memorial Sloan Kettering Cancer Center, discusses research regarding the BCMA CAR T-cell therapy ...
OncLiveTV
Sutureless glaucoma drainage valve implantation outcomes - Video 1 ID 186369
Supplementary video of original research paper: Surgical outcomes associated with a sutureless drainage valve implantation procedure in patients with ...
Dove Medical Press
